Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.

Blood cancer journal·2026
Same author

Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysis.

Frontiers in immunology·2026
Same author

Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018.

Translational cancer research·2026
Same author

Novel oral chidamide and valganciclovir regimen for EBV-PTLD post-hematopoietic stem cell transplantation: A case report.

Medicine·2026
Same author

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.

Journal of hematology & oncology·2026
Same author

Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome.

Biochemical pharmacology·2026

相关实验视频

Updated: Jul 13, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K

针对B细胞血液性恶性瘤的CD22进行向.

Jia Xu1,2, Wenjing Luo1,2, Chenggong Li3,4

  • 1Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.

Experimental hematology & oncology
|October 11, 2023
PubMed
概括

针对CD19的CAR-T细胞治疗对于B细胞癌症是有效的,但复发发生. 针对CD22的疗法为耐CD19治疗的患者提供了一个有前途的替代方案.

关键词:
在CD2222中,我们可以看到CD22.CD22 CAR-T细胞疗法CD22抗体药物联合体组合疗法是一种组合疗法.双重定位的CAR-T细胞

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K
Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

15.3K

相关实验视频

Last Updated: Jul 13, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.8K
Generation of Human CD40-activated B cells
13:27

Generation of Human CD40-activated B cells

Published on: October 16, 2009

15.3K

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 在瘤学瘤学.
  • 分子生物学分子生物学

背景情况:

  • 针对CD19的仿真抗原受体 (CAR) -T细胞疗法在B细胞恶性瘤中显示出有效性.
  • 由于CD19阴性疾病的瘤复发仍然是一个重大挑战.
  • CD22在恶性B细胞上独立于CD19表达,呈现出一种可行的替代标.

研究的目的:

  • 审查CD22.22的分子和生理特征.
  • 讨论CD22向疗法的开发和临床应用,包括抗体-药物联合体 (ADC) 和CAR-T细胞.
  • 探索克服瘤逃逸和提高治疗疗效的策略.

主要方法:

  • 对CD22特征的文献综述.
  • 对CD22ADC和CAR-T细胞的发展途径的分析.
  • 对CD22向治疗的临床数据的综合.

主要成果:

  • 针对CD22的疗法 (ADC和CAR-T细胞) 正在临床使用中,具有有前途的疗效和可接受的毒性.
  • CD22是克服CD19抗性B细胞复发的关键目标.
  • 确定的临床数据支持针对CD22的治疗潜力.

结论:

  • 针对CD22的疗法代表了管理复发或耐药B细胞恶性瘤的重要进展.
  • 对克服瘤逃生机制的进一步研究对于提高CD22向治疗结果至关重要.
  • CD22向提供了一个强大的策略,以提高B细胞癌的持续缓解率.